Since inflammatory process and oxidative damage have been implicated in neurodegenerative diseases, any AChE inhibitory agent with the additive anti-inflammatory and/or anti-oxidative effects would be expected to be superior for AD treatment [6], [7], [15]. This evidence concerns the gene ACHE and Alzheimer disease.